• Publications
  • Influence
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.
The European Cancer Anaemia Survey (ECAS) was conducted to prospectively evaluate the prevalence, incidence and treatment of anaemia (haemoglobin <12.0 g/dL) in European cancer patients, includingExpand
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
The observed differences in activity and toxicity profiles provide a basis for therapy choice and confirms the rationale for combination studies in early breast cancer. Expand
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
The difference in the time course of emesis blockade observed with two different classes of receptor antagonists provides substantial evidence for involvement of separate pathophysiological mechanisms in chemotherapy-induced vomiting. Expand
Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis.
A single dose of L-758,298 substantially suppressed the delayed nausea and vomiting characteristic of high dose cisplatin and also appeared to reduce acute emesis post-cisplatin, supporting the proposition that the underlying mechanism(s) of acute and delayed emesis are different. Expand
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Topotecan in a daily-times-five schedule is an effective regimen as second-line treatment in ovarian cancer in patients who had failed to respond to one prior cisplatin-based chemotherapeutic regimen. Expand
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
All casopitant regimens studied were more effective than the control regimen and Casopitant was generally well tolerated. Expand
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid.
A sensitive and robust method was obtained, which fulfilled all validation criteria, and accuracy varied from 91.3 to 103.6%, and imprecision did not exceed 12.7% for all analytes in plasma and oral fluid. Expand
Whole abdominopelvic radiotherapy (WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience.
IMAT was shown to be deliverable in an acceptable time slot and to produce dose distributions that are more homogeneous than those obtained with a CONV plan, with at least equal sparing of the OARs. Expand
Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma.
Clinical and pathological responses are lower in ILC compared to IDC, and patients with large ILC should preferably be offered mastectomy with immediate breast reconstruction after PCT, but PCT still remains valuable to evaluate tumor response and biologic factors in vivo. Expand
Better cosmetic results and comparable quality of life after skin-sparing mastectomy and immediate autologous breast reconstruction compared to breast conservative treatment.
The cosmetic results, assessed by the clinical team, were significantly better for patients having IBR, compared to BCS, and breast conserving treatment or mastectomy with reconstruction may yield comparable results of QoL, but cosmetic outcome is better after SSM and perforator-flap reconstruction. Expand